Company intelligence / Profile preview
Somagenetix
Zurich, Zurich, Switzerlandsomagenetix.com ↗
- Ownership
- Private
- Employees
- ~15
- Development stage
- Other
01
Overview
Somagenetix has demonstrated strong safety and efficacy for its lead candidate SGX-001 in GLP-compliant preclinical animal studies. The product has Orphan Drug Designation from both the FDA and EMA. Clinical trials are planned to start in 2026 targeting p47-CGD. The company’s novel promoter technology addresses previous limitations of viral vector-based gene therapies by ensuring specificity, long-term efficacy, and safety.
- Therapeutic areas
- ImmunologyNeurology
- Modalities
- Gene therapyLentivirus-transduced stem cell therapyEx-vivo gene therapyBiologic (by convention, as gene therapies are biologics)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Wyss Zurich Translational Center supports preclinical development of p47-CGD program.Open to strategic partnerships with pharma & biotech companies.
Beyond the preview
Go deeper on Somagenetix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Somagenetix.